You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Eli Lilly's fourth-quarter earnings come as it tries to maintain its advantage over Novo Nordisk in the GLP-1 market.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.